Testosterone Enanthate – 300
ACTIVE INGREDIENTS: Trenbolone enanthate – 300 mg.
COMPOSITION: Each 1 ml contains 300 mg of testosterone enanthate in ethyl oleate.
Formula – C26H40O3
Androgenic: 100
Anabolic: 100
INDICATIONS: Men: Testosterone enanthate is indicated for replacement therapy in conditions associated with deficiency or absence of endogenous testosterone: primary hypogonadism, testicular failure due to cryptorchidism, bilateral torsion orchitis, disappearing testicular syndrome, or orchidectomy. Hypogonadotropic hypogonadism, idiopathic gonadotropin or LHRH deficiency, or pituitary-hypothalamic damage due to tumors, trauma, or radiation. Testosterone enanthate can be used to stimulate puberty in carefully selected men with clearly delayed puberty that is not secondary to pathological disease.
Women: Testosterone enanthate may be used secondarily in women with advanced unresectable metastatic breast cancer who are 1 to 5 years postmenopausal. The main goals of therapy in these women include removal of the ovaries. This treatment has also been used in premenopausal women with breast cancer who have had an oophorectomy and are thought to have a hormone-sensitive tumor.
COMPOSITION: Each 1 ml contains 300 mg of testosterone enanthate in ethyl oleate.
Formula – C26H40O3
Androgenic: 100
Anabolic: 100
INDICATIONS: Men: Testosterone enanthate is indicated for replacement therapy in conditions associated with deficiency or absence of endogenous testosterone: primary hypogonadism, testicular failure due to cryptorchidism, bilateral torsion orchitis, disappearing testicular syndrome, or orchidectomy. Hypogonadotropic hypogonadism, idiopathic gonadotropin or LHRH deficiency, or pituitary-hypothalamic damage due to tumors, trauma, or radiation. Testosterone enanthate can be used to stimulate puberty in carefully selected men with clearly delayed puberty that is not secondary to pathological disease.
Women: Testosterone enanthate may be used secondarily in women with advanced unresectable metastatic breast cancer who are 1 to 5 years postmenopausal. The main goals of therapy in these women include removal of the ovaries. This treatment has also been used in premenopausal women with breast cancer who have had an oophorectomy and are thought to have a hormone-sensitive tumor.